FDA News Digest for November 4, 2002

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



FDA News Digest
November 4, 2002
_______________________________________________________________

Approval of Generic Version of Prilosec Called a 'Win-Win'

FDA has approved a generic version of omeprazole, allowing the first
marketing of a product that can compete with the brand-name drug Prilosec to
treat certain gastrointestinal conditions.  Health and Human Services
Secretary Tommy G. Thompson called the approval "a win-win for patients" and
added that "for those who could not afford the brand-name drug, [the
approval] means greater access to a successful medication at a lower cost."
http://www.fda.gov/bbs/topics/NEWS/2002/NEW00848.html
_______________________________________________________________

FDA Issues Alert for Mexican Cantaloupes Due to Salmonella Outbreaks

Because of unsanitary conditions that have resulted in four U.S. outbreaks
of foodborne illness due to Salmonella bacteria in the last three years, FDA
has issued an alert for cantaloupes from Mexico to be detained at all U.S.
ports.  The outbreaks are responsible for two deaths and at least 18
hospitalizations.
Release:  http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01167.html
Spanish version:
http://www.fda.gov/bbs/topics/ANSWERS/SPANISH/span01167.html
_______________________________________________________________

Infant Formula Recalled After Bacterial Contamination Found

Wyeth Nutritionals Inc. is recalling various batches of its powdered infant
formula manufactured between July 12 and Sept. 25, 2002, after FDA tests
detected the presence of Enterobacter sakazakii, a bacterium that can, in
rare cases, cause complications in infants such as meningitis (brain
inflammation) and sepsis (bacteria in the blood).  About 1.5 million cans of
milk- and soy-based formula, sold under several brand names, are being
recalled.
http://www.fda.gov/bbs/topics/NEWS/2002/NEW00849.html
_______________________________________________________________

FDA Warns Public About Possible Complications of Bone Cement

FDA has notified the public that a bone cement used to treat spinal
fractures related to the bone-thinning disorder osteoporosis has been linked
to tissue damage, nerve pain, respiratory and cardiac failure, and even
death.  The agency is working with manufacturers of orthopedic devices to
evaluate the long-term safety and effectiveness of the cement used in these
spinal procedures.
http://www.fda.gov/cdrh/safety/bonecement.html
_______________________________________________________________

Thanks for subscribing to the FDA News Digest. Our next posting will be
November 12.

To leave this list at any time, send an e-mail to
LISTSERV@LIST.NIH.GOV
In the body of the message, write
SIGNOFF FDA-NEWSDIGEST-L

[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux